Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors | Zendy

Judith E K Henning | Zendy; Timo Deutschbein | Zendy; Barbara Altieri | Zendy; Sonja Steinhauer | Zendy; Stefan Kircher | Zendy; Silviu Sbiera | Zendy; Vanessa Wild | Zendy; Wiebke Schlötelburg | Zendy; Matthias Kroiß | Zendy; Paola Perotti | Zendy; Andreas Rosenwald | Zendy; Alfredo Berruti | Zendy; Martin Faßnacht | Zendy; Cristina L. Ronchi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors

Author(s) -

Judith E K Henning,

Timo Deutschbein,

Barbara Altieri,

Sonja Steinhauer,

Stefan Kircher,

Silviu Sbiera,

Vanessa Wild,

Wiebke Schlötelburg,

Matthias Kroiß,

Paola Perotti,

Andreas Rosenwald,

Alfredo Berruti,

Martin Faßnacht,

Cristina L. Ronchi

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2017-01624

Subject(s) - medicine , gemcitabine , oncology , chemotherapy , mitotane , adrenocortical carcinoma , regimen , predictive marker , capecitabine , chemotherapy regimen , cancer , colorectal cancer

Adrenocortical carcinoma (ACC) is rare and confers an unfavorable prognosis in advanced stages. Other than combination chemotherapy with cisplatin, etoposide, doxorubicin, and mitotane, the second- and third-line regimens are not well-established. Gemcitabine (GEM)-based chemotherapy was suggested in a phase 2 clinical trial with 28 patients. In other solid tumors, human equilibrative nucleoside transporter type 1 (hENT1) and/or ribonucleotide reductase catalytic subunit M1 (RRM1) expression have been associated with resistance to GEM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research